Clinical trial
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or…
NCT00049374 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00049374 |
|---|---|
| Title | Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase II Study Of Genasense In Combination With Thalidomide And Dexamethasone In Relapsed And Refractory Multiple Myeloma |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | National Cancer Institute (NCI) NIH University of Maryland Greenebaum Cancer Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug |
| Interventions | oblimersen sodium, dexamethasone, thalidomide |
| Start date | Sep 1, 2002 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 17, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: